Now, he's part of a clinical trial at Duke Medical Center where they take out some of his own immune cells – or white blood cells – to create a vaccine.
“The vaccine programs are all geared toward letting your own immune system cure you and that's what your system is supposed to do,” Smith said.
The immune cells are given a boost at a New Jersey lab, with the help of drug company Dendreon.
“It's the patient's own immune cells which are taught essentially to, in the broad sense, taught to recognize prostate cancer cells,” Duke Medical oncologist Dr. Deborah Bradley said.
The result is a vaccine called Provenge, shipped back to the hospital in cold storage and given to the patient by infusion. The same process is repeated three times over several weeks.
“All of the processes I've had, I've really had no reaction to any of them,” Smith said.
The third phase of the trial showed great promise with a four month survival advantage, Bradley said. Though that doesn’t sound like a lot, she said, that is the median.
Smith has already survived almost nine years since his first diagnosis. An earlier vaccine trial helped put his cancer into remission, until it returned last summer. He and wife Becky are confident this vaccine will do the same and last even longer.
“I think they're on the right track of perhaps finding a cure for all types of cancers using this type of an approach, because it makes sense – it's your own body healing yourself,” Smith said.
The U.S. Food and Drug Administration could approve the vaccine on May 1.
Now, because the vaccine has shown such a benefit, Duke and a few other sites across the country now offer an open access trial, which has loosened the criteria to include more prostate cancer patients.